Treatment of T-cell LGL Leukemia When Rheumatoid Arthritis Is the Primary Indication

This protocol addresses patients with large granular lymphocytic leukaemia (LGLL) who also carry a diagnosis of rheumatoid arthritis, where the arthritis — not the leukaemia itself — is the main reason treatment is needed.

In this specific sub-population, the therapeutic focus and the choice of treating specialty shift significantly, reflecting the dominant clinical burden of the arthritic disease.

When rheumatoid arthritis drives the treatment decision, management is led primarily by rheumatologists using standard therapies for rheumatoid arthritis. Certain agents have also shown activity specifically in LGLL co-existing with rheumatoid arthritis.

The full structured regimen — including specific agents, sequencing, and clinical decision points — is available in the complete protocol below.